Foundao stories

Nov 4, 2026

Novo Nordisk raises 2026 outlook for third time on strong Wegovy pill sales

Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.

Nov 4, 20264 sources

Top claims

▪Novo Nordisk Chief Executive Officer Mike Doustdar attributed a recent flattening in Wegovy pill prescription growth to seasonal fall variations
▪Luigi La Corte, currently CFO of Galderma, was named to succeed Karsten Munk Knudsen as Chief Financial Officer of Novo Nordisk
▪Novo Nordisk's Copenhagen-listed stock fell nearly 8% in a single session in September 2026 after Novo Nordisk failed to reassure investors regarding post-Wegovy growth

Subtopics

Drug Policy, Pricing & Approval1 Eli Lilly1 Lifestyle, Wellness and Nutrition1 Novo Nordisk1 Pharmaceutical earnings1 Pharmaceutical Industry1 Prescription drug costs1 Weight loss medications & GLP-1 drugs1 Zepbound1

Related timelines